. 2020 Oct 6;24(2):56–61. doi: 10.1136/ebmental-2020-300184

Table 1.

Trial characteristics of the analytic dataset

Authors	N	Sex	Mean age (SD)	Assessments available for linkage by visit	Trial inclusion criteria
Rogers and Friedhoff²⁹	156	Male: 63 Female: 93	71.9 (7.4)	ADAS-Cog, MMSE 0, 1, 3, 6, 9, 12	MMSE: 10–26 CDR: 1 or 2
Rogers et al ²³	481	Male: 176 Female: 305	74.0 (7.6)	ADAS-Cog, MMSE 0, 3, 6, 9, 12	MMSE: 10–26 CDR: 1 or 2
Rogers et al ³⁰	473	Male: 180 Female: 293	73.5 (7.2)	ADAS-Cog, MMSE 0, 6, 12, 18, 24	MMSE: 10–26 CDR: 1 or 2
Black et al ¹⁶	342	Male: 101 Female: 241	78.1 (7.6)	MMSE: 0 to 24 SIB: −1, 8, 16, 24	MMSE: 1–12 Modified Hachinski Ischemic Score: 6 or less Functional Assessment Staging: 6 or more
Farlow et al ²⁴	1444	Male: 539 Female: 905	74.2 (7.9)	MMSE, SIB 0, 6, 12, 18, 24	MMSE: 0–20 SIB: 90 or less Cornell Scale for Depression in Dementia score: under 12

Week −1 refers to the screening assessment that was 28±7 before the drug administration (mean 23.67 days).

ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive Subscale; CDR, Clinical Dementia Rating; MMSE, Mini-mental State Examination; SIB, Severe Impairment Battery.